Vitality Biopharma
1901 Avenue of the Stars, 2nd Floor
Los Angeles
California
90067
United States
Tel: 530-231-7800
Website: http://vitality.bio/
Email: info@vitality.bio
About Vitality Biopharma
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.LEADERSHIP:
Founder: Robert Brooke, and Avtar Dhillon
Founder (Scientific): Brandon Zipp, PhD
CEO: Robert Brooke
FOLLOW VITALITY BIOPHARMA:
Tweets by Vitality Biopharma
20 articles about Vitality Biopharma
-
Vitality Biopharma Receives DEA Renewal for Cannabinoid Pharma Development ProgramApproval of Vitality research program and manufacturing operations through May 2019
6/20/2018
Vitality Biopharma, Inc. announced that it has received approval from both the U.S. Drug Enforcement Administration (DEA) and the State of California Research Advisory Panel which permits the Company to continue development of its novel cannabinoid pharmaceutical prodrugs.
-
Vitality Biopharma Announces Publication Of International PCT Patent Filing
10/18/2017
Vitality Biopharma announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.
-
Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough
10/4/2017
-
Vitality Biopharma Receives Updated SeeThruEquity Price Target Of $2.40
9/29/2017
-
Vitality Biopharma To Present At The Moneyshow San Francisco Conference
8/23/2017
-
Vitality Biopharma Releases Positive Results For Treatment Of Inflammatory Bowel Disease
7/19/2017
-
Vitality Biopharma Advisor To Present Pediatric IBD Case Study At ICRS2017 In Montreal
6/23/2017
-
Vitality Biopharma Advisor To Present At 11th National Clinical Conference On Cannabis Therapeutics
5/18/2017
-
Vitality Biopharma Announces Positive Results For Cannabinoid Antibiotics
5/11/2017
-
Vitality Biopharma Adds Key Clinical Advisors In Gastroenterology
5/4/2017
-
Vitality Biopharma Releases Clinical Report Of Cannabinoid Therapy For Pediatric IBD
4/21/2017
-
Vitality Biopharma Appoints Pharma Industry Veteran To Advance Cannabosides Regulatory Development
4/12/2017
-
Vitality Biopharma Announces Positive Results For Colon Cancer
3/31/2017
-
Vitality Biopharma Publishes Scientific Data On Discovery Of Cannabinoid Glycosides
2/1/2017
-
Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility
12/21/2016
-
Vitality Biopharma Advances Cannabosides For Treatment Of Narcotic Bowel Syndrome
11/17/2016
-
Vitality Biopharma Announces International Patent Filing For Cannabinoid Pharmaceuticals
11/11/2016
-
Vitality Biopharma Develops Cannabinoid Alternatives To Opiate Prescription Pain Medications
9/14/2016
-
Vitality Biopharma To Present At Rodman & Renshaw 18th Annual Global Investment Conference
9/13/2016
-
Vitality Biopharma Announces Expansion Of Prodrug Pharmaceutical Portfolio
8/25/2016